Rivaroxaban: 2034 patent, 19 approved ANDAs | Phontix AI
Orange Book lists patent 9,539,218 on Xarelto 10, 15 and 20 mg to Feb 2034 (Aug 2034 with pediatric entry). FDA shows 19 approved generic applications.
Read MoreHome / Resources
Resources
Briefs, thinking pieces and case studies from the categories we track. Every figure traces to a named source, and anything modelled says so. Sample reports ask for your work email.
Insights
Articles, blogs and case studies from the categories we track. Each piece carries its method and its sources.
ArticlesEvidence-led explainers and research on the markets we track.Explore Articles →
BlogsPerspectives on emerging signals, methods and market changes.Explore Blogs →
Case StudiesResearch decisions and outcomes across the markets we track.Explore Case Studies →14 resources · Page 2 of 2
Denosumab biosimilars: the US launch queue and Amgen's sales
US denosumab biosimilars entered from 2 June 2025 on reported settlement dates. Amgen's global Prolia sales fell 33% and Xgeva 31% in H1 2026.
Read MoreEliquis generics: 1 April 2028 is not an Orange Book date
In 2021 the Bristol Myers Squibb-Pfizer Alliance gave 1 April 2028 as the earliest US generic date, subject to appeals. The Orange Book lists other dates.
Read MoreEU Bisphenol A Food-Contact Ban, Deadline by Deadline
Regulation 2024/3190 sets four dates for BPA in EU food contact materials. Which one applies depends on the article and when it was first placed.
Read MoreIndia's Epoxy Resin Duty: What Changed
India's anti-dumping duty on liquid epoxy resin began in November 2025. Customs data shows imports level and the origin mix changed. What a buyer can do.
Read MoreIndia's Phenol Anti-Dumping Case: Seven Origins
DGTR's phenol anti-dumping case names seven origins. Customs data shows who supplied India in FY2025-26 and January to July 2026, and what a buyer can do.
Read MoreKeytruda Loss of Exclusivity: IV vs Qlex Dates
Merck lists US patent expiry for IV Keytruda at 2028 and Keytruda Qlex at 2043. Qlex is a separate FDA licence, BLA 761467. Sources read 15 to 23 Oct 2026.
Read MoreVedolizumab biosimilars: US lawsuits and London claims
Takeda has sued two vedolizumab biosimilar developers in New Jersey on six patents. Google Patents puts their anticipated expiry at 2 May 2032.
Read MoreA Recommendation Is Not a Duty.
In India, a DGTR finding is only a recommendation. The Finance Ministry decides whether it becomes a duty, and the record on that step has moved sharply.
Read MoreFirst to file is not first to launch: the Entyvio race
Three vedolizumab biosimilar applications have been announced as accepted for FDA review. Why the order of announcements does not decide who sells first.
Read MoreOne Company, Two Anticoagulants, Two Different Records
Aurobindo holds FDA approvals for generic rivaroxaban and apixaban. One has a US product listed for sale and the other does not. What each record shows.
Read MorePhenol and Acetone: One Price Problem
Phenol and acetone come out of one reactor. Customs data from India and Europe shows acetone's import value rose twice as fast as phenol's in 2026.
Read MoreWestlake Did Not Blame the BPA Ban for Closing Pernis. The Record Cannot Say More.
Westlake's filing gives its European business, not the EU BPA ban, as the reason to close Pernis. What the dates and import data can and cannot show.
Read MoreWhat MSN’s Entresto Court Win Did and Did Not Decide
In July 2025 a US court held Novartis had not proved MSN infringed one Entresto patent. The FDA register lists ten generic applications dated before that.
Read MoreNo resources match these filters. Try another topic or search.
Sample reports
Real output formats with sample data, so you can see what a subscriber receives.
LOE Edge
Dupilumab in atopic dermatitis: exclusivity timeline, evidence tiers and calculation trail.
Get the samplePrice Fundamentals
Polymeric MDI into India: price history, landed-cost build-up and the flagged freight gap.
Get the sampleRegister your interest in new articles
Choose the topics you would like to hear about. This records your preference; automated newsletter delivery is not configured yet.
Want the analysis applied to your category?
Most of what we publish started as a question someone asked. Bring us yours.